IDH2 and acute myeloid leukemia: Indeed, excess D2HG produced by IDH mutant AML blasts confers susceptibility to venetoclax due to ETC dysregulation, suggesting why patients carrying IDH1/IDH2 mutations have more robust responses to the combination treatment of venetoclax and azacitidine.